Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.

ABSTRACT:

Background

Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients.

Methods

Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients.

Results

We identified a pan

SUBMITTER: Kuo IY 

PROVIDER: S-EPMC4057483 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature